1) Wang Z, Klipfell E, Bennett BJ, et al:Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:57-63, 2011
2) Tang WH, Wang Z, Fan Y, et al:Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure:refining the gut hypothesis. J Am Coll Cardiol 64:1908-1914, 2014
3) Li XS, Obeid S, Klingenberg R, et al:Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes:a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J 38:814-824, 2017
4) Tang WH, Wang Z, Kennedy DJ, et al:Gut microbiota-dependent trimethylamine N-oxide（TMAO）pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 116:448-455, 2015
5) Zhu W, Gregory JC, Org E, et al:Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165:111-124, 2016
6) Organ CL, Otsuka H, Bhushan S, et al:Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail 9:e002314, 2016
7) Wang Z, Roberts AB, Buffa JA, et al:Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163:1585-1595, 2015
8) Cho CE, Taesuwan S, Malysheva OV, et al:Trimethylamine-N-oxide（TMAO）response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition:A randomized controlled trial. Mol Nutr Food Res 61:doi:10.1002/mnfr. 201600324, 2017
9) Pastori D, Carnevale R, Nocella C, et al:Gut-derived serum lipopolysaccharide is associated with enhanced risk of major adverse cardiovascular events in atrial fibrillation:effect of adherence to Mediterranean diet. J Am Heart Assoc 6:e005784, 2017
10) Zuo K, Li J, Li K, et al:Disordered gut microbiota and alterations in metabolic patterns are associated with atrial fibrillation. Gigascience 8. pii:giz058, 2019
11) Niebauer J, Volk HD, Kemp M, et al:Endotoxin and immune activation in chronic heart failure:a prospective cohort study. Lancet 353:1838-1842, 1999
12) Sandek A, Bauditz J, Swidsinski A, et al:Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 50:1561-1569, 2007
13) Sandek A, Bjarnason I, Volk HD, et al:Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol 157:80-85, 2012
14) Suzuki T, Heaney LM, Bhandari SS, et al:Trimethylamine N-oxide and prognosis in acute heart failure. Heart 102:841-848, 2016
15) Kamo T, Akazawa H, Suda W, et al:Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure. PLoS One 12:e0174099, 2017
16) Luedde M, Winkler T, Heinsen FA, et al:Heart failure is associated with depletion of core intestinal microbiota. ESC Heart Fail 4:282-290, 2017
17) Falony G, Joossens M, Vieira-Silva S, et al:Population-level analysis of gut microbiome variation. Science 352:560-564, 2016
18) Pasini E, Aquilani R, Testa C, et al:Pathogenic gut flora in patients with chronic heart failure. JACC Heart Fail 4:220-227, 2016
19) Hayashi T, Yamashita T, Watanabe H, et al:Gut microbiome and plasma microbiome-related metabolites in patients with decompensated and compensated heart failure. Circ J 83:182-192, 2018
20) Suzuki T, Yazaki Y, Voors AA, et al:Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure:results from BIOSTAT-CHF. Eur J Heart Fail 21:877-886, 2019
21) Cui X, Ye L, Li J, et al:Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci Rep 8:635, 2018
ログイン
ランキング
お知らせ
ログイン
